Treatment with liraglutide-a once-daily GLP-1 analog-does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug

Journal of Clinical Pharmacology

Volumn 51, Issue 12, 2011, Pages 1696-1703

  Jacobsen, Lisbeth V ^a   Vouis, Jan ^b   Hindsberger, Charlotte ^a   Zdravkovic, Milan ^a  

^a NOVO NORDISK A S   (Denmark)

^b IQVIA   (United States)

Author keywords

drug interactions; Liraglutide; oral contraceptives; pharmacokinetics

Indexed keywords

ETHINYLESTRADIOL PLUS NORGESTREL; LIRAGLUTIDE;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DYSPEPSIA; ERUCTATION; FEMALE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; ORAL CONTRACEPTION; PLASMA CLEARANCE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CONTRACEPTIVES, ORAL, COMBINED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHINYL ESTRADIOL; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; LEVONORGESTREL; MIDDLE AGED; POSTMENOPAUSE;

EID: 82955241439     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010389471     Document Type: Article

References (23)

1. European Medicines Agency (EMA). Summary of product characteristics- Victoza. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/001026/WC500050017.pdf. Accessed September 8, 2010.
2. Food and Drug Administration (FDA). Victoza prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022341lbl.pdf. Accessed September 8, 2010.
3. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000 ; 43: 1664-1669 (Pubitemid 30304999)
4. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009 ; 26: 268-278
5. Nauck MA, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care. 2009 ; 32: 84-90
6. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009 ; 373: 473-481
7. Zinman B, Gerich J, Buse J, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care. 2009 ; 32: 1224-1230
8. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia. 2009 ; 52: 2046-2055
9. Buse J, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label study (LEAD-6). Lancet. 2009 ; 374: 39-47
10. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002 ; 45: 195-202 (Pubitemid 34208381)
11. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997 ; 273 (5 pt 1). E981 - E988 (Pubitemid 27505833)
12. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002 ; 359: 824-830 (Pubitemid 34233752)
13. Kapitza C, Flint A, Hindsberger C, Zdravkovic M. The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol. Diabetes. 2008 ; 57 (suppl 1). A593
14. Malm-Erjefält M, Ekblom M, Brøndsted L, Vouis J, Lennernäs H, Zdravkovic M. A randomised, doubleblind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects. Diabetes. 2008 ; 57 (suppl 1). A130
15. Egarter C, Topcuoglu MA, Imhof M, et al. Low dose oral contraceptives and quality of life. Contraception. 1999 ; 59: 287-291 (Pubitemid 29406029)
16. Shenfield G. Drug interactions with oral contraceptive preparations. Med J Aust. 1986 ; 17 (144). 205-211 (Pubitemid 16079616)
17. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly, Washington 2002; and Note of Clarification on Paragraph 30 by the WMA General assembly, Tokyo 2004. http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed March 3, 2010.
18. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Harmonised Tripartite Guideline. Good Clinical Practice. http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf. Accessed March 3, 2010.
19. Food and Drug Administration (FDA). Guidance for Industry. In vivo drug metabolism/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling. U.S. Department of Health and Human Services. Food and Drug Administration. November1999. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072119.pdf. Accessed March 3, 2010.
20. European Medicines Agency (EMEA). Note for guidance on the investigation of drug interactions. CPMP/EWP/560/95, 17 December 1997. http://www.ema.europa. eu/pdfs/human/ewp/056095en.pdf. Accessed March 3, 2010.
21. KotharePSegerMMaceK. Effects of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women. AAPS J. 2007;9(suppl 2):Abstract 554. www.aapsj.org/abstracts/AM-2007/AAPS2007-000554.PDF. Accessed March 3, 2010.
22. Blode H, Schürmann R, Benda N. Novel ethinyl estradiol-beta- cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone. Contraception. 2008 ; 77: 171-176
23. Edelman A, Carlson NE, Cherala G, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception. 2009 ; 80: 119-127